Day 1 – Wednesday September 13

09:00 LSX Welcome Address

Caitlin McNally, Conference Director, LSX

---

09:15 Keynote Panel: Acquisition A-Game - Strategies For Securing Success  

Despite global disruptions and slowdown in IPO and SPAC activity in 2022, the final quarter of the 2022 saw an increase in M&A deal-making in the medtech industry. Whilst not hitting the heights of previous years, industry financing remains robust for the right innovations, and the demographic shift and the growth in the consumer health sector is offering new opportunities for medtech companies. However, competition for funds and opportunities is fierce, making it crucial for medtech companies to develop sound business strategies and position themselves for long-term success. A panel of experienced medtech industry experts will discuss how medtech companies can bolster their M&A and business development strategies in 2024  

• How to become a sought-after M&A target for medtech companies  
• What are the growth opportunities in the medtech industry for 2023 and 2024? 
• Successful M&A deals and the strategies behind them  
• The impact of early and high-risk acquisitions on the medtech industry 

Antonio Sánchez-Cordero, Vice President, Strategy & Business Development (M&A), Specialty Diagnostics Group, Thermofisher
Dan Wolf, SVP, Baxter
Christos Monovoukas, VP, Business Development and Strategy, Zimmer Biomet
Kristine Ilaria, VP of Corporate Development, Smith & Nephew

---

10:10 Fireside Chat: A Deal Well Done – M&A & Strategic Partnerships

Saurabh Bhasin, SVP Corporate Development M&A, Fresenius Kabi
Jørgen Bundgaard Hansen, Former CEO, Ivenix

---

10:30 Morning Break

---

11:00 Keynote Panel: Diagnostic Disruption - The Evolving Landscape Of Medtech Diagnostics  

The American healthcare system, with among the world’s highest healthcare costs, continually focusses heavily on reactive treatment. With successive and concurrent crises, there is a need more than ever before, for proactive diagnostic and preventative care. With the IVD sector tipped as the largest device area by 2028, coupled with the digital transformation of the industry, the opportunity in this sector is ever-growing. A panel of diagnostic industry leaders discuss how medtech companies can tap into this sectors growth and how to traverse potential obstacles.  

• Unlocking the potential of point-of-care diagnostics  
• Breaking down the barriers to diagnostic innovation  
• Navigating the regulatory landscape for diagnostics  
• Avoiding common pitfalls in diagnostic development  
• Charting the future of diagnostics: from real-world evidence to remote patient monitoring 

Joachim Reischl, Head of Innovation, Diagnostics and Precision Medicine, Danaher
Anh Hoang, CEO, Jana Care
Giles Hamilton, Former CEO, ODx Innovations 
Tom Miller, Founder and Managing Partner, Greybird Ventures 

---

12:00 Panel: Global Market Access - The Medtech Maze Across Europe, US, And China             

The global medtech market access landscape presents a complex maze for companies to navigate. With globally unique requirements and regulations in a rapidly evolving industry, knowing where to start can be a challenge in itself. A panel of market access leaders discuss the differing paths to market worldwide, their unique challenges and opportunities and how medtech companies can best position themselves to get their product to the payer.   

• How to navigate and comply with the regulations and requirements for different countries and regions 
• How to effectively adapt products and services to meet the unique cultural and healthcare needs of different patient populations 
• Best practices for building partnerships and collaborations with local organizations and stakeholders to facilitate market access and ensure successful implementation of products and services              

Brian Hakim, Director of International Business Development, MedTecX 
Shani Noel, Director, Market Access & Managed Care, Respiratory Health, Baxter 
Martin Gershon, Managing Partner and CIO, Endeavor Venture Fund 
Michelle Costa, Director, Global & U.S. Health Economics Market Access, Johnson & Johnson MedTech 

---

12:45 Lunch Break

---

13:40 Panel: FDA Focus - Steering Clear Of Regulatory Roadblocks

The US medtech industry is a global leader. However, for both domestic and international companies, navigating the complex regulatory landscape in the US can be a significant challenge. With recent changing documentation in the realms of digital health and AI, it is essential that companies stay abreast of changing regulations. A panel of industry regulatory experts discuss how companies can build a robust regulatory strategy.

• Understanding FDA requirements and guidance for different medical devices and building relationships with FDA and other regulatory bodies
• Utilizing industry groups and advocacy organizations for regulatory developments and advocacy, and developing a strong pre-submission strategy
• Building a team with expertise in regulatory affairs and quality management.
• Building a strong clinical evidence package, leveraging FDA's expedited pathways for innovative products, and building a strong post-market surveillance plan
• Partnering with other companies to share resources and expertise in navigating the regulatory environment

Simon Mason, President, NESTcc 
Sergio Gadaleta, SVP, Regulatory Affairs & Quality Assurance, 3M
Phil Lavin, Founder & Managing Partner, Melior Capital Management  

---

14:30 Panel: Funding For Growth - Planting Seeds For Medtech Success In A Competitive Landscape

The current investment landscape remains competitive despite high-costs, regulatory hurdles, and reimbursement uncertainty. With incubators and accelerators supporting start-ups by providing resources, mentorship, and networking opportunities, it’s not of question of where the money is, but how to access it. In an oversaturated market, it is essential companies can stand -out and attract top funds. A panel of top medtech investors discuss the current investment environment and what they look for in potential partnerships.

• Current trends and opportunities in the US medtech market and how to capitalize on them
• Differentiating from competitors and developing a strong business plan to attract investors
• Benefits of working with incubators and accelerators
• Building a strong team, network of advisors and key metrics and data to communicate value proposition and demonstrate ability to achieve sustainable revenue growth to potential investors

Jonathan Gertler, Managing Director, BioVentures MedTech Funds
David Kereiakes, Partner, Providence Ventures 
Daniel Gottlieb, Associate Director, Broadview Ventures

---

15:30 Afternoon Break

---

16:00 Panel: Taking The Pulse Of Digital Health - A Home Run For Medtech?

Digital transformation of medtech is here to stay, and with growth in telemedicine, point of care and an increasing focus on the ‘hospital at home’, there is a dramatic reshaping of the industry. Whilst a source of ongoing opportunity for entrepreneurs, increasing digital footprints are not without their challenges. As current transformation has matured, there is increasing observation of privacy, security and ethical concerns. Additionally, reimbursement and regulatory compliance in previously uncharted waters need to be addressed. The industry continues to see rapid change without losing steam, with new technology and approaches continually emerging. Without getting caught up in the buzz, medtech companies need to ensure their new tech meets the needs of both patient and healthcare providers. A panel of industry leaders discuss how they keep pace of recent developments and how medtech companies should approach digital transformation and health. 

• How digital transformation has affected the industry to date, and current trends
• How to implement medtech digital transformation in 2023 and beyond
• Understanding customer requirements and considering the patient journey
• Redefining organisational structure and business models to successfully adapt digital technologies
• Tackling privacy, security, reimbursement, and regulatory concerns 

Ryan Lakin, Divisional VP, Digital Solutions, Abbott 
René Bastón, VP Strategic Alliances, Team8 Health 
Cait Brumme, CEO, MassChallenge 
Marina Massingham, CEO, Aifred Health 

---

17:00 Panel: Beyond Mergers And Investment: Unleashing Innovation And Growth Through Strategic Partnership
 
In today's fast-changing and ever-evolving business landscape, strategic partnerships have become an increasingly popular and effective way for companies to drive innovation and growth. A panel of experts from MedExec Women delve into the world of strategic partnerships beyond traditional mergers and investments. Exploring various partnership frameworks such as joint development agreements, licensing agreements, co-marketing, R&D partnerships, supply chain partnerships, and joint ventures. 
 

• Finding the right partner: Discuss criteria for evaluating potential partners, such as complementary technology, shared goals, and cultural fit
• Partnership agreements: Best practices for negotiating complex partnership agreements, including key terms and provisions to include
• Measuring success: Different metrics for measuring success, such as revenue growth and product launch, and how to track progress over time

Maria Shepherd, Executive Board Member, MedExecWomen
Martha Shadan, President & CEO, Miach Orthopaedics
Nancy Briefs, President & CEO, AltrixBio
Denise Clarke, Director, Strategy and Business Development Precision Diagnosis, Philips 

---

17:40 Drinks Reception

 

Day 2 – Thursday, September 13

 

09:00 LSX Welcome Address

---

09:15 Keynote Panel:  Medtech Evolution: Harnessing The Power Of Innovation For A Better Healthcare System

The innovation environment is rapidly evolving and presents a wealth of opportunities for companies to make an impact. With a massive pipeline of technologies, there is an abundance of potential for new and exciting products to be developed. However, with this potential comes challenge, including the need for end-to-end solutions, incorporating the voice of the clinician, and providing not just the product but the training to use it. Even before prototyping, there is a need to consider how hospitals will adopt the product, including buying, storing and reimbursement codes, as well as the explosion of data and the risk of clinician burnout. The industry is at a turning point, and those who can navigate these challenges will be well-positioned to make a real difference in the healthcare system. A panel of industry leaders discuss how medtech companies need to companies can succeed in an increasingly saturated market.

• Delivering cutting-edge solutions that cater to the ever-evolving needs of the healthcare system
• Incorporating the valuable insights of medical professionals to craft user-friendly and highly effective products
• Equipping users with the skills and knowledge to utilize the products to their fullest potential for optimal results
• Charting a smooth path for hospital adoption by tackling buying, storing, and reimbursement challenges head-on
• Tackling the data deluge and clinician burnout through savvy data management strategies to ensure efficient and effective healthcare delivery

Keith Boettiger, President, Abbott Heart Failure, Abbott 
Joseph Smith, Chief Scientific Officer, BD
Jennifer Joe, Global Medical Strategy & Population Health Director, AstraZeneca
Stuart Hart, Chief Medical Officer, Integra LifeSciences  

---

10:15 Morning Break

---

11:00 Panel: Green And Clean – Why ESG Should Be A Priority

Medtech companies are facing a growing emphasis on Environmental, Social, and Governance (ESG) considerations, as investors and stakeholders look for companies with a strong commitment to sustainability, social responsibility, and ethical practices. However, companies face unique challenges in implementing such policies, when balancing these commitments with regulatory compliance and high R&D costs. Despite these challenges, medtech companies that prioritise ESG considerations can reap benefits such as cost reduction, improved reputation, and talent attraction. As healthcare shifts towards value-based care, companies with strong ESG practices will be well-positioned to meet the needs of health-conscious consumers. A panel of industry leaders discuss why medtech CEO’s should push ESG policies up their priority list. 

• Key Environmental, Social, and Governance (ESG) considerations for medtech companies and how they align with industry regulations and compliance
• Strategies for medtech companies to effectively integrate ESG considerations into R&D, manufacturing, and operations processes
• Benefits and challenges of implementing sustainable practices in the medtech industry and best practices for measuring and reporting ESG performance
• Financial, reputational, and legal implications of not addressing ESG considerations for medtech companies.
• ESG opportunities and challenges in the field of digital health and telemedicine
• Are ESG policies a ‘must-have’ for future acquisition potential?

Moderator: Scott Daubin, Partner, Bain & Co
Baker Flagg, Lean Transformation Leader, GE Healthcare  
Andrew Meadow, General Partner, Health Innovation Capital  

---

12:00 Panel: CVC Collaboration - Building Winning Partnerships

As the medtech industry continues to evolve and innovation becomes increasingly important, many small and medium-sized medtech companies are turning to corporate venture capital (CVC) as a source of funding and strategic support. CVC allows these companies to tap into the resources and expertise of larger, established players in the industry, while also providing an opportunity for these larger companies to access new technologies and business models. However, for medtech companies, navigating the CVC landscape can be tricky. This panel will bring together industry experts to discuss the role of CVC in the medtech industry and provide insights on what medtech companies need to know in order to be successful in securing CVC funding. 

• Finding the perfect CVC partner for your company
• What CVCs look for in medtech companies
• Making strategic connections and leveraging CVC relationships to gain access to valuable resources and networks
• Balancing autonomy and expectations in a successful CVC partnership

Oliver Keown, Managing Partner, Intuitive Ventures
Lana Caron, Sr Director, Philips Ventures
Kadir Kadhiresan, VP, Venture Investments, Johnson & Johnson Innovation
Alex de Winter, Vice President of New Ventures, Danaher Ventures

---

13:00 Lunch Break

---

14:00 Panel: Chain Reaction - Keeping The Medtech Industry's Supply Chain On Track

Being a sector heavily reliant on complex global supply chains, disrupted by a variety of factors, including natural disasters, geopolitical tensions, and trade disputes, there is pressure for companies to increase their agility. Additionally, as the industry becomes more digitized and data-driven, there is an increased need for secure and reliable data management and communication throughout the supply chain. Industry leaders are now investing in strategies to improve supply chain resilience, such as diversifying suppliers and implementing real-time data analytics. A panel of industry leaders discuss how companies can increase their supply chain resiliency.

• What are the top-notch risk management strategies of market-leading medtech companies and how they protect their supply chain from potential threats
• How to ensure an uninterrupted supply of vital medical equipment and devices even in the face of disruptions
• How market leaders handle and tackle supply chain disruptions with quick and effective action
• Evaluating and selecting suppliers, maintaining strong supplier relationships, and monitoring supplier performance to ensure quality and compliance

Jerry Wang, Vice President of Global Supply Chain, Terumo Cardiovascular
Michael Galleno, SVP Supply Chain Management, Laboratory Diagnostics, Siemens Healthineers 

---

14:40 Panel: Designed To Last – Developing Future-Proof Innovations

Although producing essential products and somewhat shielded with what the economy can throw at them, medtech companies are facing an increasingly oversaturated market. Companies need to have data-driven strategies and technologies in place to demonstrate their value to investors, clients, and regulators. These macroeconomic factors coupled with a shifting healthcare system and increasing digital transformation requires companies to shift their thinking on product design and manufacturing to build recurrent revenue streams and ensure true value for their customers. Key leaders in product design and development discuss considerations and potential challenges for companies taking their product off the page and into the market.

• How to incorporate a measured, structured, and data-driven approach in product design and manufacturing
• How to improve efficiency and reduce costs via outsourcing
• Transferring to a Medtech as a service (MTaaS) model across the device classes
• Subscription based models and reaching low-income markets
• MTaaS model and the relationship with healthcare providers

Mark Guarraia, VP Design & User Experience, Novo Nordisk
Manisha Shah-Bugaj, CEO, Activ Surgical
Hung-Hsiang Chen, Head of User Insights & Design, ConvaTec  
Rami Ibrahim, Global Head of Innovation, Halma  

---

15:20 Closing Keynote Panel: Health Equity – Confronting Racial Bias, Promoting Inclusion And Improving Diversity

Racial bias, lack of inclusion and diversity in the medtech industry is a critical issue that negatively impacts patient care and outcomes. Research in women’s health, and studies inclusive of minority populations has been historically neglected. This is demonstrated in historical lack of funding in these areas, the use of biased data and AI models which inaccurately reflecting the needs and experiences of diverse patient populations. This results in suboptimal care and unequal healthcare outcomes for women and minority populations. Key thought leaders discuss how the current medtech industry is and isn’t addressing health inequities and how medtech companies can bridge the gap. 

• Avoiding biased data and AI during ongoing digital transformation of the industry
• Current systemic road-blocks preventing medtech companies from bridging health inequity and how these can be navigated
• The importance of addressing sex/gender specific issues in medtech design and development
• How can the FDAs regulatory framework be used to promote both women’s and minority population’s health
• Key initiatives to address health inequities and implement diverse clinical studies

Tenley Koepnick, Vice President, Global Clinical Research, Edwards Lifesciences
Tracy MacNeal, President, CEO, Materna Medical  
Paula Miller, Director of Diversity, Equity, Inclusion and Belonging, iRhythm Technologies, Inc. 
Sarah Hassaine, Head of Diversity & Inclusion, ResMed  

---

16:00 Close of Congress

---